231 related articles for article (PubMed ID: 17548120)
1. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity.
Lazar C; Durantel D; Macovei A; Zitzmann N; Zoulim F; Dwek RA; Branza-Nichita N
Antiviral Res; 2007 Oct; 76(1):30-7. PubMed ID: 17548120
[TBL] [Abstract][Full Text] [Related]
2. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion.
Lu X; Mehta A; Dwek R; Butters T; Block T
Virology; 1995 Nov; 213(2):660-5. PubMed ID: 7491790
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of host ER glucosidase activity prevents Golgi processing of virion-associated bovine viral diarrhea virus E2 glycoproteins and reduces infectivity of secreted virions.
Jordan R; Nikolaeva OV; Wang L; Conyers B; Mehta A; Dwek RA; Block TM
Virology; 2002 Mar; 295(1):10-9. PubMed ID: 12033761
[TBL] [Abstract][Full Text] [Related]
4. Antiviral effects of glycosylation and glucose trimming inhibitors on human parainfluenza virus type 3.
Tanaka Y; Kato J; Kohara M; Galinski MS
Antiviral Res; 2006 Oct; 72(1):1-9. PubMed ID: 16730076
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications.
Mehta A; Carrouée S; Conyers B; Jordan R; Butters T; Dwek RA; Block TM
Hepatology; 2001 Jun; 33(6):1488-95. PubMed ID: 11391538
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity.
Blanchet M; Sureau C
J Virol; 2006 Dec; 80(24):11935-45. PubMed ID: 17020942
[TBL] [Abstract][Full Text] [Related]
7. [Affect of deoxynojirimycin derivatives on hepatitis C virus morphogenesis].
Timokhova AV; Bakinovskiĭ LV; Zinin AI; Popenko VI; Ivanov AV; Rubtsov PM; Kochetkov SN; Belzhelarskaia SN
Mol Biol (Mosk); 2012; 46(4):644-53. PubMed ID: 23113354
[TBL] [Abstract][Full Text] [Related]
8. Novel imino sugar α-glucosidase inhibitors as antiviral compounds.
Howe JD; Smith N; Lee MJ; Ardes-Guisot N; Vauzeilles B; Désiré J; Baron A; Blériot Y; Sollogoub M; Alonzi DS; Butters TD
Bioorg Med Chem; 2013 Aug; 21(16):4831-8. PubMed ID: 23582447
[TBL] [Abstract][Full Text] [Related]
9. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity.
Gripon P; Le Seyec J; Rumin S; Guguen-Guillouzo C
Virology; 1995 Nov; 213(2):292-9. PubMed ID: 7491754
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological characterisation of novel N-alkyl-deoxynojirimycin alpha-glucosidase inhibitors.
Rawlings AJ; Lomas H; Pilling AW; Lee MJ; Alonzi DS; Rountree JS; Jenkinson SF; Fleet GW; Dwek RA; Jones JH; Butters TD
Chembiochem; 2009 Apr; 10(6):1101-5. PubMed ID: 19294724
[TBL] [Abstract][Full Text] [Related]
11. Posttranslational N-glycosylation of the hepatitis B virus large envelope protein.
Lambert C; Prange R
Virol J; 2007 May; 4():45. PubMed ID: 17537250
[TBL] [Abstract][Full Text] [Related]
12. Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers.
Branza-Nichita N; Durantel D; Carrouée-Durantel S; Dwek RA; Zitzmann N
J Virol; 2001 Apr; 75(8):3527-36. PubMed ID: 11264342
[TBL] [Abstract][Full Text] [Related]
13. Involvement of endoplasmic reticulum in hepatitis B virus replication.
Xia W; Shen Y; Xie H; Zheng S
Virus Res; 2006 Nov; 121(2):116-21. PubMed ID: 16870295
[TBL] [Abstract][Full Text] [Related]
14. Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors.
Chapel C; Garcia C; Bartosch B; Roingeard P; Zitzmann N; Cosset FL; Dubuisson J; Dwek RA; Trépo C; Zoulim F; Durantel D
J Gen Virol; 2007 Apr; 88(Pt 4):1133-1143. PubMed ID: 17374756
[TBL] [Abstract][Full Text] [Related]
15. Natural iminosugar derivatives of 1-deoxynojirimycin inhibit glycosylation of hepatitis viral envelope proteins.
Jacob JR; Mansfield K; You JE; Tennant BC; Kim YH
J Microbiol; 2007 Oct; 45(5):431-40. PubMed ID: 17978803
[TBL] [Abstract][Full Text] [Related]
16. Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases.
Asano N; Nishida M; Kato A; Kizu H; Matsui K; Shimada Y; Itoh T; Baba M; Watson AA; Nash RJ; Lilley PM; Watkin DJ; Fleet GW
J Med Chem; 1998 Jul; 41(14):2565-71. PubMed ID: 9651160
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment.
Xie HY; Xia WL; Zhang CC; Wu LM; Ji HF; Cheng Y; Zheng SS
Acta Pharmacol Sin; 2007 Jul; 28(7):975-84. PubMed ID: 17588333
[TBL] [Abstract][Full Text] [Related]
18. Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus.
Jaoudé GA; Sureau C
J Virol; 2005 Aug; 79(16):10460-6. PubMed ID: 16051838
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.
Villet S; Billioud G; Pichoud C; Lucifora J; Hantz O; Sureau C; Dény P; Zoulim F
Gastroenterology; 2009 Jan; 136(1):168-176.e2. PubMed ID: 18996386
[TBL] [Abstract][Full Text] [Related]
20. Glucosidase inhibitors as antiviral agents for hepatitis B and C.
Durantel D; Alotte C; Zoulim F
Curr Opin Investig Drugs; 2007 Feb; 8(2):125-9. PubMed ID: 17328228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
